Comparison and evaluation of non-invasive models in predicting liver inflammation and fibrosis of chronic hepatitis B virus-infected patients with high hepatitis B virus DNA and normal or mildly elevated alanine transaminase levels

Lingmei Wang, MA, Jiao Li, MA, Kai Yang, MD, Hao Zhang, MA, Qin Wang, PhD, Xiongwen Lv, MD, Shihe Guan, MD

Abstract

Few studies have paid attention to the performances of non-invasive models in diagnosing stages of liver fibrosis and inflammation, which are critical for early and accurate assessment of prognostication and decisions on antiviral treatment in chronic hepatitis B infection patients with high hepatitis B virus DNA and normal or mildly elevated alanine transaminase levels (≤2 times upper limit of normal (ULN)). This study aimed to investigate the value of routine serum markers in evaluation of liver inflammation and fibrosis in these patients.

A total of 370 consecutive chronic hepatitis B virus-infected patients who underwent liver biopsy were retrospectively analyzed. The Scheuer scoring system was adopted as the pathological standard for diagnosing liver inflammation and fibrosis. The receiver-operating characteristic curves (ROC) and the area under the ROC curves (AUROCs) were used to analyze the performances of the models, including aspartate transaminase to platelet ratio index (APRI), fibrosis index based on the four factors (FIB-4), red cell volume distribution width-to-platelet ratio (RPR), globulin-platelet model (GP), and gamma-glutamyl transpeptidase to platelet ratio index (GPR).

To predict significant inflammation (G ≥ 2), the AUROC of APRI was higher than that of FIB-4 (0.705 vs 0.629, P = .001), RPR (0.705 vs 0.593, P < .001) and GP (0.705 vs 0.620, P = .002), equivalent to that of GPR (0.705 vs 0.690, P = .606). As for severe inflammation (G ≥ 3) and significant fibrosis (≥S2), there was no statistic difference among them. To predict severe fibrosis (≥S3), the AUROC of FIB-4 was higher than that of RPR (0.805 vs 0.750, P = .006) and GP (0.805 vs 0.755, P = .046), comparable to that of APRI (0.805 vs 0.785, P = .550) and GPR (0.805 vs 0.818, P = .694). As for significant liver histological changes (G ≥ 2 or/and S ≥ 2), the performance of APRI was higher than that of RPR (0.717 vs 0.652, P = .006), GP (0.717 vs 0.659, P = .011), equivalent to that of FIB-4 (0.717 vs 0.692, P = .254) and GPR (0.717 vs 0.680, P = .166).

We found that APRI, GPR, and FIB-4 were more effective than RPR and GP for diagnosing liver inflammation and fibrosis.

Abbreviations: ALT = alanine transaminase, APRI = aspartate transaminase to platelet ratio index, AST = aspartate aminotransferase, FIB-4 = fibrosis index based on the four factors, GGT = gamma-glutamyl transpeptidase, GP = globulin-platelet model, GPR = gamma-glutamyl transpeptidase to platelet ratio index, HBV = hepatitis B virus, RPR = red cell volume distribution width-to-platelet ratio, ULN = upper limit of normal.

Editor: Sherief Abd-Elalim.

This research was supported by the National Science Foundation of China (81972013), the Class A Project of the Key Research and Development Programs of the Science and Technology Department of Anhui Province (180408020236), and the Key Project of the Natural Science Foundation of Anhui Province (KJ2018A0206).

The authors have no conflicts of interest to disclose.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

*Department of Clinical Laboratory, The Second Hospital of Anhui Medical University, †The Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, School of Pharmacy, Anhui Medical University, Hefei, China.

Correspondence: Shihe Guan, Department of Clinical Laboratory, The Second Hospital of Anhui Medical University, Furong Road 678 #, Hefei 230601, Anhui, China (e-mail: shiheguan@126.com); Xiongwen Lv, The Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, School of Pharmacy, Anhui Medical University, Meishan Road 18 #, Hefei 230601, Anhui, China (e-mail: lvx1288@aliyun.com).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Wang L, Li J, Yang K, Zhang H, Wang G, Lv X, Guan S. Comparison and evaluation of non-invasive models in predicting liver inflammation and fibrosis of chronic hepatitis B virus-infected patients with high hepatitis B virus DNA and normal or mildly elevated alanine transaminase levels. Medicine 2020;99:23 (e20548).

Received: 14 October 2019 / Received in final form: 24 April 2020 / Accepted: 3 May 2020

http://dx.doi.org/10.1097/MD.0000000000020548
1. Introduction
Hepatitis B virus (HBV) infection is still a major public health problem worldwide, which may cause hepatocellular necrosis and inflammation, even serious complications including cirrhosis with end-stage liver disease and hepatocellular carcinoma. At present, it is estimated that there are about 70 million chronic carriers of HBV surface antigen (5% to 6% prevalence) and 0.5 million newly diagnosed cancer cases annually in China. [2-4]

To reduce the burden of HBV infection, the early and accurate diagnosis of liver inflammation and fibrosis, as well as the treatment with antiviral therapy may be critical. Although liver biopsy has been recommended as the gold standard method to assess the degree of fibrosis, it was limited because of its high cost and invasive procedure, which might cause the risks of bleeding and pneumothorax. [5] Recently, serum biomarkers including the aspartate aminotransferase-to-platelet ratio index (APRI), the fibrosis index based on the four factors (FIB-4), and Fibroscan have been recommended by the WHO as alternatives for liver biopsy.[6] Compared with the Fibroscan requiring the high cost of the equipment and trained operator, blood or serum indices are more available, simple and practical for the most public particularly in resource-limited settings. In addition, the innovative non-invasive models based on serum markers have been developed, including the red cell volume distribution width-to-platelet ratio (RPR), [7-9] globulin-platelet model (GP), [10-12] and the gamma-glutamyl transeptidase-to-platelet ratio (GPR), [13-15] which are still under controversy in HBV-infected patients.

Liver fibrosis is a compensatory repair process involved hepatic inflammation. The serum alanine transaminase (ALT), a cytoplasmic enzyme in hepatocytes, is usually used to identify liver cell injury and its level ≥2 ULN is adopted as 1 of the criterions for antiviral treatment in CHB patients. [16] However, some recent studies suggested that patients with “normal” ALT might still suffer from liver histological changes even need antiviral therapy. [17] Given the spectrum of disease and natural history of chronic HBV infection diverse, according to the WHO guidelines,[6,18] the non-invasive fibrosis models should be used alongside the clinical criteria and other laboratory criteria (ALT and HBV DNA levels). Therefore, we evaluated the clinical significances of the above five non-invasive models in diagnosing liver inflammation and fibrosis, as well as significant liver histological changes in chronic HBV-infected patients with high HBV DNA and normal or mildly elevated ALT levels.

2. Materials and methods
2.1. Patients
The electronic medical records of chronic HBV-infected patients who underwent liver biopsy at a university-based hospital (the Second Hospital of Anhui Medical University), from January 2012 to April 2019 were retrospectively reviewed. According to the guidelines, serum HBV DNA was tested by real-time PCR (ABI 7500, Applied Biosystems, Foster City, CA). The lower limit of the assay was 500 IU/mL. Hepatitis B surface antigen and e antigen HBeAg were tested by the Architect i2000 analyser (Abbott Diagnostics, Chicago). The non-invasive models were calculated in accordance with the following formulas:

\[
\text{APRI} = \frac{(\text{AST} / \text{ULN}) \times 100}{\text{platelet count} (10^9/L)}
\]

\[
\text{FIB} - 4 = \frac{(\text{age} \times \text{AST} (\text{IU/L}) / \text{platelet count} (10^9/L) \times [\text{ALT} (\text{IU/L})^{1/2}])}{\text{platelet count} (10^9/L)}
\]

\[
\text{RPR} = \frac{\text{RDW} (\%)/\text{PLT} (10^9/L)}{\text{platelet count} (10^9/L)}
\]

\[
\text{GP} = \frac{(\text{GGT} / \text{ULN})}{\text{platelet count} (10^9/L)}
\]

(1) age ≥18 years;
(2) the persistent presence of HBsAg for more than 6 months;
(3) HBV DNA ≥ 20 000 IU/mL;
(4) ALT ≤ 2 ULN (the ULN of ALT is 50 UL/L);
(5) with liver biopsy and routine laboratory tests.

The exclusion criteria were as follows:
(1) coinfection with HCV, HDV or HIV;
(2) a history of alcohol consumption (>20 g/d);
(3) concomitant other chronic liver diseases, such as nonalcoholic fatty liver disease, autoimmune liver disease;
(4) antiviral therapy within 1 year;
(5) with liver cirrhosis, decompensated liver disease, hepatocellular carcinoma, or any other type of cancer.

Finally, 370 HBV-infected patients were included in this study. This study was approved by our institutional review board (approval number: 20190251) and all patients have signed informed consent that their clinical data can be used in clinical studies before admission.

2.2. Liver histological examination
Liver biopsies were performed via percutaneous echo-assisted method and a minimum of 6 portal tracts is needed. Slides were viewed and read by pathologists (D.C.), who were unaware of patients’ identity and history. Biopsies were classified into stages according to the Scheuer scoring system,[19] G 0-4 and S 0-4. In this study, significant fibrosis and severe fibrosis were defined as pathological stage ≥ S2 and ≥ S3, respectively. Significant inflammation and severe inflammation were defined as pathological stage ≥ G2 and ≥ G3, respectively.

2.3. Routine laboratory tests
All patients had routine laboratory blood tests about a week before biopsy based on the manufacturer’s instructions. The liver function tests including albumin, globulin, ALT, aspartate aminotransferase (AST), gamma-glutamyl transeptidase (GGT) were detected by full-automated biochemistry analyser AU5800 (Beckman Coulter, California). Blood routine tests including platelet count, and red cell distribution width were measured by using automated hematology analyser Sysmex XT-2000i (Sysmex, Kobe, Japan). HBV DNA level was quantified by real-time PCR (ABI 7500, Applied Biosystems, Foster City, CA). The lower limit of the assay was 500 IU/mL. Hepatitis B surface antigen and e antigen HBeAg were tested by the Architect i2000 analyser (Abbott Diagnostics, Chicago). The non-invasive models were calculated in accordance with the following formulas:

\[
\text{APRI} = \frac{(\text{AST} / \text{ULN}) \times 100}{\text{platelet count} (10^9/L)}
\]

\[
\text{FIB} - 4 = \frac{(\text{age} \times \text{AST} (\text{IU/L}) / \text{platelet count} (10^9/L) \times [\text{ALT} (\text{IU/L})^{1/2}])}{\text{platelet count} (10^9/L)}
\]

\[
\text{RPR} = \frac{\text{RDW} (\%)/\text{PLT} (10^9/L)}{\text{platelet count} (10^9/L)}
\]

\[
\text{GP} = \frac{(\text{GGT} / \text{ULN})}{\text{platelet count} (10^9/L)}
\]
Table 1
Demographic and biochemical characteristics of the study participants.

|                    | All Patients (n = 370) | GO- 1 (n = 272) | G2- 4 (n = 98) | S0- 1 (n = 249) | S2- 4 (n = 121) | P value |
|--------------------|------------------------|-----------------|----------------|-----------------|-----------------|---------|
| Male, n(%)         | 247 (66.8%)            | 182 (66.9%)     | 65 (66.3%)     | 158 (63.5%)     | 89 (73.6%)      | .053    |
| HBeAg + (%)        | 273 (73.8%)            | 205 (75.4%)     | 68 (69.4%)     | 200 (80.3%)     | 73 (60.3%)      | <.001   |
| Age (y)            | 34.5 (28.0, 42.0)      | 34.0 (27.0, 42.0)| 35.5 (28.0, 43.3)| 33.0 (27.0, 41.0)| 37.0 (30.0, 44.5)| .001   |
| Albunin (g/L)      | 40.8 (38.1, 43.4)      | 40.5 (37.9, 43.1)| 41.7 (38.4, 44.6)| 40.7 (38.1, 43.2)| 40.8 (37.7, 44.1)| .773    |
| Globulin (g/L)     | 26.3 (23.7, 29.5)      | 26.0 (23.7, 29.4)| 27.8 (24.3, 29.9)| 26.2 (24.0, 29.4)| 26.7 (23.6, 29.7)| .920    |
| ALT (U/L)          | 44.5 (27.0, 62.3)      | 41.0 (25.0, 57.8)| 50.0 (39.0, 74.5)| 42.0 (25.0, 62.0)| 48.0 (36.0, 63.0)| .015    |
| AST (U/L)          | 31.5 (24.0, 42.0)      | 28.0 (23.0, 38.8)| 40.0 (30.5, 53.0)| 28.0 (22.0, 40.0)| 37.0 (28.0, 47.0)| <.001   |
| GGT (U/L)          | 19.0 (14.0, 26.8)      | 26.0 (17.8, 41.2)| 30.0 (19.7, 48.0)| 19.0 (14.0, 27.0)| 25.0 (17.0, 40.0)| <.001   |
| RDW (%)            | 12.9 (12.5, 13.4)      | 12.9 (12.5, 13.4)| 13.0 (12.6, 13.6)| 12.9 (12.5, 13.4)| 13.0 (12.7, 13.4)| .136    |
| PLT (10^9/L)       | 176 ± 54               | 179 ± 53        | 162 ± 54       | 184 (154, 218)  | 144 (107, 185)  | <.001   |
| HBV DNA (fg IU/mL) | 6.94 (5.58, 7.73)      | 7.17 (5.65, 7.81)| 6.49 (5.44, 7.42)| 7.32 (6.22, 7.87)| 5.90 (5.07, 7.08)| <.001   |

ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyl transpeptidase, HBeAg = hepatitis B e antigen, PLT = platelet count, RDW = red cell distribution width.

Table 2
Correlations between noninvasive fibrosis models and liver Scheuer score.

|                | Inflammatory activity | Fibrosis stage |
|----------------|-----------------------|----------------|
|                | Spearman’s r          | P value        | Spearman’s r          | P value        |
| ALT            | 0.262                 | <.001          | 0.136                  | <.001          |
| APRI           | 0.313                 | <.001          | 0.396                  | <.001          |
| FIB-4          | 0.194                 | <.001          | 0.391                  | <.001          |
| RPR            | 0.146                 | .005           | 0.339                  | <.001          |
| GP             | 0.186                 | <.001          | 0.332                  | <.001          |
| GPR            | 0.293                 | <.001          | 0.339                  | <.001          |

Table 3
Performances of serum markers for the diagnosis of liver inflammation.

To predict severe inflammation (G ≥ 3), APRI and GPR could predict liver inflammation, but there was no statistic difference between them.

ALT is a marker of cytolysis and it is usually used as a traditional marker for the evaluation of the liver inflammatory activity.[20] The diagnostic performances of different NITs were presented in Table 3 and Figure 1. Not all indexes could predict liver inflammation compared with FIB-4, the AUROC of APRI was superior in predicting patients with G ≥ 2 inflammation (0.705 vs 0.629, P = .001), but no difference compared with GPR (0.705 vs 0.690, P = .606), ALT (0.705 vs 0.672, P = .289). The optimal cut-off values for diagnosing G ≥ 2 inflammation were 0.65 for APRI, 1.22 for FIB-4, 0.07 for RPR, 1.5 for GP, 0.18 for GPR, and 44 for ALT, respectively.

As for severe inflammation (G ≥ 3), APRI and GPR could predict liver inflammation, but there was no statistic difference between them.

Table 4
Performances of non-invasive fibrosis models for the diagnosis of liver fibrosis.

All indexes could predict liver fibrosis (Table 4 and Fig. 2). To diagnose S ≥ 2 liver fibrosis, the AUROCs were 0.729 for APRI, 0.722 for FIB-4, 0.690 for RPR, 0.686 for GP, and 0.688 for GPR, respectively. However, there was no difference among them to predict significant fibrosis. By maximizing Youden index, the optimal cut-off values for the prediction of significant fibrosis were 0.54 for APRI, 1.35 for FIB-4, 0.09 for RPR, 1.5 for GP, and 0.42 for GPR, respectively.

To predict severe fibrosis (S ≥ 3), the AUROCs for non-invasive fibrosis models were increased greatly with different degrees. Among them, FIB-4 was superior to RPR (0.805 vs 0.750,
The natural history of chronic HBV infection is dynamic and complex. What is more, it may cause a markedly increased risk of hepatocellular carcinoma in chronic hepatitis patients while antiviral therapy has been shown to reduce the risk. [21,22] Therefore, it is important to identify patients with liver inflammation and fibrosis in the clinical practice so that the treatment and hepatocellular carcinoma surveillance can be started. However, the lack of simple and convenient evaluations remains a major problem in clinical practice especially in resource-limited area. Recently, although several indexes have been supposed to be the substitute for biopsy, the measurement

3.5. Performances of non-invasive fibrosis models for the diagnosis of significant liver histological changes

The presence of significant liver injury especially fibrosis suggests the need for immediate antiviral therapy even if ALT ≥ 2 ULN, therefore, ≥ S2 or/and ≥ G2 were put into 1 group as significant liver histological changes. The AUROCs of them were all slightly decreased compared with that in the single evaluation of liver fibrosis, while increased compared with that in the single evaluation of liver inflammation. As for the estimation the AUROCs to predict significant histological changes, the performance of APRI was higher than that of RPR (0.717 vs 0.652, P = .006) and GP (0.805 vs 0.755, P = .046), but comparable to APRI (0.805 vs 0.785, P = .550) and GPR (0.805 vs 0.818, P = .694). Maximizing Youden’s index for the prediction of severe fibrosis, the cut-off values were 0.54 for APRI, 1.5 for FIB-4, 0.09 for RPR, 2.24 for GP, and 0.45 for GPR, respectively.

4. Discussion

The natural history of chronic HBV infection is dynamic and complex. What is more, it may cause a markedly increased risk of hepatocellular carcinoma in chronic hepatitis patients while antiviral therapy has been shown to reduce the risk. [21,22] Therefore, it is important to identify patients with liver inflammation and fibrosis in the clinical practice so that the treatment and hepatocellular carcinoma surveillance can be started. However, the lack of simple and convenient evaluations remains a major problem in clinical practice especially in resource-limited area. Recently, although several indexes have been supposed to be the substitute for biopsy, the measurement

![Figure 1. ROC curves of serum marks for diagnosing G ≥ 2(A) and G ≥ 3(B). APRI = aspartate transaminase-to-platelet ratio index, FIB-4 = fibrosis index based on the four factors, RPR = red cell volume distribution width-to-platelet ratio, GP = globulin-platelet model, GPR = gamma-glutamyl transpeptidase to platelet ratio index, ALT = alanine aminotransferase.](image-url)
The diagnostic performance of markers for predicting liver fibrosis.

| AUROC(95%CI) Cut-off | Se (%) | Sp (%) | PLR | NLR | PPV (%) | NPV (%) | P value | P value |
|---------------------|--------|--------|------|------|---------|---------|---------|---------|
| ≥S2 | APRI | 0.729 (0.681–0.774) | 0.54 | 66.9 | 69.9 | 2.2 | 0.5 | 51.9 | 81.3 | <.001 | .765 |
| | | 0.5 | 69.4 | 63.9 | 1.9 | 0.5 | 48.3 | 81.1 | | |
| | | 1.5 | 5.5 | 98.4 | 3.6 | 1.0 | 63.6 | 68.2 | | |
| | FB-4 | 0.722 (0.674–0.767) | 1.35 | 57.9 | 83.5 | 3.5 | 0.5 | 63.1 | 80.3 | <.001 | - |
| | | 1.45 | 55.4 | 85.9 | 3.9 | 0.5 | 65.7 | 79.9 | | |
| | | 3.25 | 7.4 | 98.4 | 4.6 | 0.9 | 69.2 | 68.6 | | |
| | RPR | 0.690 (0.640–0.737) | 0.09 | 47.9 | 84.7 | 3.1 | 0.6 | 60.4 | 77.0 | <.001 | .107 |
| | | 1.5 | 75.2 | 54.6 | 1.7 | 0.5 | 44.6 | 81.9 | <.001 | .124 |
| | GP | 0.689 (0.638–0.739) | 0.42 | 38.0 | 91.2 | 4.3 | 0.7 | 67.6 | 75.2 | <.001 | .230 |
| | GPR | 0.785 (0.740–0.826) | 0.54 | 84.2 | 62.7 | 2.3 | 0.3 | 20.5 | 97.2 | <.001 | .550 |
| | | 0.805 (0.761–0.844) | 0.5 | 73.7 | 79.2 | 3.6 | 0.3 | 28.9 | 96.3 | <.001 | - |
| | | 0.750 (0.702–0.793) | 0.09 | 63.2 | 78.1 | 2.9 | 0.5 | 25.0 | 94.9 | <.001 | .006 |
| | | 2.24 | 55.3 | 87.4 | 4.4 | 0.5 | 33.3 | 94.5 | <.001 | .046 |
| | | 0.818 (0.775–0.868) | 0.45 | 65.8 | 88.3 | 5.6 | 0.4 | 39.1 | 95.8 | <.001 | .694 |

APRI = aspartate transaminase-to-platelet ratio index, AUROC = area under the receiver operating characteristic curve, FIB-4 = fibrosis index based on the four factors, GP = globulin-platelet model, GPR = gamma-glutamyl transpeptidase to platelet ratio index, NLR = negative likelihood ratio, NPV = negative predictive value, PLR = positive likelihood ratio, PPV = positive predictive value, RPR = red cell volume distribution width-to-platelet ratio.

*Compared with FB-4.

The accuracy of liver fibrosis and liver inflammation was controversial. Therefore, this study aimed to evaluate the diagnostic performances of indexes for liver fibrosis and inflammation in chronic HBV-infected patients with high HBV DNA and normal or mildly elevated ALT levels.

In the present study, of 370 HBV-infected patients, 26.5% (98/370) of the patients had significant hepatic inflammation (G2–4) and 32.7% (121/370) had significant liver fibrosis (S2–4). On the whole, 40.5% (150/370) indicated significant liver histological changes (G ≥ 2 or S ≥ 2). Meanwhile, in those patients with “normal” ALT, G ≥ 2 and G ≥ 3 were 36/208 (17.3%) and 6/208 (2.9%), S ≥ 2 and S ≥ 3 were 59/208 (28.3%) and 20/208 (9.6%), respectively, which, reflected that patients with “normal” ALT did not mean exclusion of histological disease to some extent. Using ALT alone seems likely not enough to predict liver inflammation. However, compared with FB-4, RPR and GP, the AUROCs of APRI was significantly higher in patients with G ≥2, but not superior to ALT and GPR. In this way, the results indicated that those non-invasive models did not show distinct advantage over ALT to predict significant inflammation (G ≥2). However, when it came to G ≥3, there was only 15 cases enrolled, which did not present remarkable differences between APRI and GPR. Overall, these non-invasive fibrosis models did not show much advantage like Wu’s study. GPR, firstly reported in 2015, showed more accuracy than classical biomarkers APRI and FIB-4 to stage liver fibrosis in patients with chronic HBV infection in West Africa and China. However, it did show controversial advantage in some Chinese cohorts later. Though based on the large sample over 1000 patients regardless of e antigen status and viral load, the accuracy of GPR to diagnose fibrosis and cirrhosis was different from that of APRI and FIB-4. Ming-Jian Lian revealed that the AUROC of GPR for the prediction of significant fibrosis, severe fibrosis, and cirrhosis were 0.733, 0.777, and

Figure 2. ROC curves of noninvasive models for diagnosing S ≥ 2(A) and S ≥ 3(B). APRI = aspartate transaminase-to-platelet ratio index, FIB4 = fibrosis index based on the four factors, RPR = red cell volume distribution width-to-platelet ratio, GP = globulin-platelet model, GPR = gamma-glutamyl transpeptidase to platelet ratio index.
The diagnosis of significant liver histological changes. APRI = aspartate transaminase-to-platelet ratio index, AUROC = area under the receiver operating characteristic curve, FIB-4 = fibrosis index based on the four factors, GP = globulin-platelet model, GPR = gamma-glutamyl transpeptidase to platelet ratio index. NLR = negative likelihood ratio, NPV = negative predictive value, PLR = positive likelihood ratio, PPV = positive predictive value. RPR = red cell volume distribution width-to-platelet ratio. Se = sensitivity, Sp = specificity.

Compared with APRI.

Table 5

| Marker | AUROC (95%CI) | Cut-off | Se (%) | Sp (%) | PLR | NLR | PPV (%) | NPV (%) | P value | P value |
|--------|--------------|---------|--------|--------|-----|-----|---------|---------|---------|---------|
| APRI   | 0.717 (0.668–0.762) | 0.65 | 82.0 | 62.3 | 2.9 | 0.6 | 66.7 | 71.5 | <.001 | .17 |
| FIB-4  | 0.692 (0.642–0.738) | 1.98 | 65.0 | 82.3 | 3.1 | 0.6 | 65.7 | 72.4 | <.001 | .254 |
| RPR    | 0.652 (0.601–0.701) | 0.09 | 41.3 | 84.6 | 2.7 | 0.7 | 64.6 | 67.9 | <.001 | .006 |
| GP     | 0.659 (0.608–0.707) | 1.5  | 71.3 | 55.9 | 1.6 | 0.5 | 52.5 | 74.1 | <.001 | .11 |
| GPR    | 0.680 (0.629–0.727) | 0.18 | 77.7 | 51.8 | 1.6 | 0.4 | 52.3 | 77.0 | <.001 | .166 |

APRI = aspartate transaminase to platelet ratio index, AUROC = area under the receiver operating characteristic curve, FIB-4 = fibrosis index based on the four factors, GP = globulin-platelet model, GPR = gamma-glutamyl transpeptidase to platelet ratio index. NLR = negative likelihood ratio, NPV = negative predictive value, PLR = positive likelihood ratio, PPV = positive predictive value. RPR = red cell volume distribution width-to-platelet ratio. Se = sensitivity, Sp = specificity.

Compared with APRI.

0.796, respectively, by the analysis of 10 studies including 5882 patients with HBV infection. Meanwhile, it suggested that GPR had moderate diagnostic accuracy but did not compare the difference between classical serum models and itself.[27] In the present study, GPR was comparable to other serum markers in predicting significant liver histological changes.

For RPR, more than one study suggested that it was a strong predictor of the degree of fibrosis and cirrhosis in CHB patients.[7–9] Similarly, Chen et al proposed that RPR could predict significant fibrosis and cirrhosis in CHB patients with relatively high accuracy than FIB-4 and APRI, suggesting the application of this index may reduce the need for liver biopsy in CHB patients.[30] However, in this study, RPR was inferior to APRI and FIB-4 in diagnosing hepatic inflammation and fibrosis, which was in consistent with Xiaojuan Wu’s study.[14] This was further confirmed by Minhui Dong’s investigations,[28] which compared the diagnostic accuracy of 17 models in treatment-naïve CHB patients. Some researchers recommended stepwise applying RPR and other markers to free proportion of HBV-related patients from liver biopsies in detecting significant fibrosis and cirrhosis.[31,32]

APRI and FIB-4, recommended by WHO as alternatives for liver biopsy, have faced challenges after new innovative models continuously proposed.[10,13,15,23,28,30] The results indicated that the 2 formulas had similar diagnostic accuracy in predicting fibrosis, while APRI was superior to FIB-4 in predicting inflammation. Their performances were not inferior to others in the diagnosis of fibrosis by the observation of continuous articles.[11,12,14,24,26] The cut-off values of APRI and FIB-4 obtained by maximizing the sum of sensitivity for the diagnosis of significant fibrosis were 0.54 and 1.35, which were close to the low cut-off values (0.5 and 1.45) recommended by WHO guidelines. When chose the high cut-off (1.5) to predict significant fibrosis recommended by WHO guidelines, the sensitivity decreased and specificity increased. Of note, when we put ≥S2 or ≥G2 into 1 group as significant liver histological changes, the emerging models did not show any advantages over the classical APRI and FIB-4 in the measurement of significant histological changes which may be the primary indication for treatment initiation in patients with HBV-infected.[6]

The discrepancies among the 5 non-invasive models for the diagnosis of liver diseases could be due to the specific inclusion and exclusion criteria, different pathological scoring systems, individual variation, and genetic factors. There were also some defects in the present study. First, the retrospective design might have caused selective bias, which may result in misestimated sensitivity and specificity of indexes. Second, the relatively small number of patients with G ≥3 (15 patients, 4.1%) unavoidably led to statistical bias when evaluating and comparing the performances of serum models. Third, FibroScan result was not included although many studies reported it had a good performance in the identification of liver fibrosis.
In conclusion, the study showed that serum ALT was not inferior to APRI and GPR in diagnosis of liver moderate inflammation (G ≥ 2) for chronic HBV infection patients with HBV DNA ≥ 20000 IU/mL and ALT ≤ 2ULN. APRI and GPR were more effective than FIB-4, RPR and GP for diagnosing liver significant inflammation (G ≥ 2), equal to others in diagnosing severe inflammation (G ≥ 3) and significant fibrosis (S ≥ 2). As for the diagnosis of advanced fibrosis (S ≥ 3) and significant liver histological changes, the APRI, FIB-4 and GPR showed advantage over the others. From this study, it appears that GPR, APRI and FIB-4 might be the most useful models to evaluate liver disease progression and to decide on the treatment in patients for the specific population. Further study is required to validate these non-invasive models in a clinical practice.

Acknowledgment
The authors thank F.M. Pan for his assistance in the statistical analysis.

Author contributions
Conceptualization: Wang LM, Li J, Yang K and Zhang H.
Data curation: Wang Q and Zhang H.
Formal analysis: Wang LM, Li J, Yang K and Zhang H.
Validation: Wang LM and Wang Q.
Writing – original draft: Wang LM.
Writing – review & editing: Guan SH and Lv XW.

References
[1] Shih C, Yang CC, Choijilsuren G, et al. Hepatitis B Virus. Trends Microbiol 2018;26:386–7.
[2] Razav-Sharzer D, Garmkredliz I, Nguyen MH. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018;3:383–403.
[3] Liu J, Zhang S, Wang Q, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21–49 years in rural China: a population-based, cross-sectional study. Lancet Infect Dis 2016;16:80–6.
[4] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32.
[5] Puccinno F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68 276 biopsies. J Hepatol 1986;2:165–73.
[6] Guidelines for the prevention, care, and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015.
[7] Taefi A, Huang CC, Kolli K, et al. Red cell distribution width to platelet ratio, a useful indicator of liver fibrosis in chronic hepatitis patients. Hepatol Int 2015;9:454–60.
[8] Yoon D, Zhuhua T, Haujun W, et al. Predictive value of the red blood cell distribution width-to-platelet ratio for hepatic fibrosis. Scand J Gastroenterol 2019;54:81–6.
[9] Karazor E, Ulcay A, Tanoglu A, et al. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients. Eur J Gastroenterol Hepatol 2014;26:1320–4.
[10] Coskun BD, Almnkaya E, Sevinc E, et al. The diagnostic value of a globulin/platelet model for evaluating liver fibrosis in chronic hepatitis B patients. Rev Esp Enferm Dig 2015;170:740–4.
[11] Liu XD, Wu J, Liang J, et al. Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients. World J Gastroenterol 2012;18:2784–92.
[12] Li Q, Lu C, Li W, et al. Globulin-platelet model predicts significant fibrosis and cirrhosis in CHB patients with high HBV DNA and mildly elevated alanine transaminase levels. Clin Exp Med 2018;18:71–8.
[13] Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut 2016;65:1369–76.
[14] Zhang W, Sun M, Chen G, et al. Reassessment of gamma-glutamyl transpeptidase to platelet ratio (GPR): a large-sample, dynamic study based on liver biopsy in a Chinese population with chronic hepatitis B virus (HBV) infection. Gut 2018;67:988–91.
[15] Liu DP, Lu W, Zhang QZ, et al. Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B. J Viral Hepat 2018;25:581–9.
[16] Kew MC. Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet 2000;355:591–2.
[17] Nguyen MH, Garcia RT, Trinh HN, et al. Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels. Am J Gastroenterol 2009;104:2206–13.
[18] Terrault NA, Browey NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261–83.
[19] EMB. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000;31:241–6.
[20] Kim WR, Flamm SL, Di Bisceglie AM, et al. Public Policy Committee of the American Association for the Study of Liver Disease. APRI, FIB-4, and RPR as a candidate indicator of health and disease. HEPATOBIOLOGY 2008;47:1563–70.
[21] Varbohitis I, Papatheodoridis GV. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol 2016;22:319–26.
[22] Papatheodoridis GV, Chan HL, Hansen BE, et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015;62:956–67.
[23] Dufour DR. Alanine aminotransferase: is it healthy to be “normal”? Hepatology 2009;50:1699–701.
[24] Wu X, Cai B, Su Z, et al. Aspartate transaminase to platelet ratio index and gamma-glutamyl transpeptidase-to-platelet ratio outweigh fibrosis index based on four factors and red cell distribution width-platelet ratio in diagnosing liver fibrosis and inflammation in chronic hepatitis B. J Clin Lab Anal 2018;32:e22341.
[25] Li Q, Li W, Huang Y, et al. The gamma-glutamyl transpeptidase-to-platelet ratio predicts liver fibrosis and cirrhosis in HBsAg-positive chronic HBV infection patients with high HBV DNA and normal or mildly elevated alanine transaminase levels in China. J Viral Hepat 2016;23:912–9.
[26] Huang R, Wang G, Tian C, et al. Gamma-glutamyl-transpeptidase to platelet ratio is not superior to APRI, FIB-4 and RPR for diagnosing liver fibrosis in CHB patients in China. Sci Rep 2017;7:8543.
[27] Lian MJ, Zhang JQ, Chen SD, et al. Diagnostic accuracy of gamma-glutamyl transpeptidase-to-platelet ratio for predicting hepatitis B-related fibrosis: a meta-analysis. Eur J Gastroenterol Hepatol 2019;31:399–406.
[28] Dong M, Wu J, Yu X, et al. Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in Chinese hepatitis B patients. Liver Int 2018;38:1362–70.
[29] Dong XQ, Wu Z, Zhao H, et al. China Hep B RFARGEvaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chronic hepatitis B patients. J Viral Hepat 2019;26:297–307.
[30] Chen B, Ye B, Zhang J, et al. RDW to platelet ratio: a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B. PLoS One 2013;8:e68780.
[31] Chen YP, Hu XM, Liang XE, et al. Stepwise application of fibrosis index based on four factors, red cell distribution width-platelet ratio, and aspartate aminotransferase-platelet ratio for compensated hepatitis B fibrosis detection. J Gastroenterol Hepatol 2018;33:256–63.
[32] Zhu MY, Zou X, Li Q, et al. A novel noninvasive algorithm for the assessment of liver fibrosis in patients with chronic hepatitis B virus infection. J Viral Hepat 2017;24:589–98.